Spirogen Purchased for Up to $440 Million

Oct 15, 2013


British drugmaker AstraZeneca said to bolster its research and development pipeline in oncology, its MedImmune unit would buy biotech company Spirogen for up to $440 million.

Spirogen focuses on antibody-drug conjugate technology, which has the potential to directly target cancer tumors while safeguarding healthy cells, AstraZeneca said. They said it would pay an initial $200 million plus a further $240 million if Spirogen meets development targets.

AstraZeneca will also pay $20 million to take an equity investment in Swiss-based ADC Therapeutics, which has a licensing agreement with Spirogen. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments